Species differences in β-oxidative metabolism of a thromboxane A₂-receptor antagonist [(+)-S-145] in rat, dog and monkey

References

• ARAI, M., SERIZAWA, N., TERAHARA, A., TRuptA, Y., HORIE, M. and BABA, S., 1988, Pravastatin sodium (CS-514), a novel cholesterol-lowering agent which inhibits HMG-CoA reductase. Sankyo Kenkyusho Nempo, 40, 1–38.
   Google Scholar
• ARIMURA, A., ASANUMA, F., KUROSAWA, A., HARADA, F., NAGAI, H. and KOD A., 1992, Antiasthmatic activity of a novel thromboxane A2 antagonist, S-1452, in guinea pig. International Archives of Allergy and Immunology, 98, 239–246.
   PubMed Web of Science ®Google Scholar
• BLACK, A. E., HAS, R. M., ROTH, B. D., Woo, P. and WOOLF, T. F., 1999, Metabolism and excretion of atorvastatin in rats and dogs. Drug Metabolism and Disposition, 27, 916–923.
   PubMed Web of Science ®Google Scholar
• BOBERG, M., ANGERBAUER, R., KANHAI, W. K., KARL, W., KERN, A., RADTKE, M. and STENKE, W., 1998, Biotransformation of cerivastatin in mice, rats, and dogs in vivo. Drug Metabolism and Disposition, 26, 640–652.
   PubMed Web of Science ®Google Scholar
• DICZFALUSKY, U., 1994, O-Oxidation of eicosanoids. Progress in Lipid Research, 33, 403–428.
   PubMedGoogle Scholar
• GUZMAN, M. and GEELEN, M. J. H., 1993, Regulation of fatty acids oxidation in mammalian liver. Biochimica et Biophysica Acta, 1167, 227–241.
   PubMedGoogle Scholar
• HALPIN, R. A., ULAL E. H., TILL, A. E., KARL P. H., VYAS, K. P., HUNNINGKAKE, D. B. and DUGGAN, D. E., 1993, Biotransformation of lovastatin: species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metabolism and Disposition, 21, 1003–1011.
   Google Scholar
• HANASAKI, K., NAGASAKI, T. and ARITA, H., 1989, Characterization of platelet thromboxane A2/ prostaglandin H2 receptor by a novel thromboxane receptor antagonist, [3H]S-145. Biochemical Pharmacology, 38, 2007–2017.
   PubMed Web of Science ®Google Scholar
• HILTUNEN, J. K., FILPPILA, S. A., HAYRINEN, H. M., KOIVURANTA, K. T. and HAKKOLA, E. H., 1993, Peroxisomal O-oxidation of poly unsaturated fatty acids. Biochimie, 75, 175–182.
   PubMedGoogle Scholar
• HUTT, J. A. and CALDWELL, J. 1992, Amino acid conjugation. In G. J. Mulder (ed.), Conjugation Reactions in Drug Metabolism (London: Taylor & Francis) pp. 273–305.
   Google Scholar
• KRISANS, S. K., MORTENSEN, R. M. and LAZAROW, P. B., 1980, Acyl-CoA synthetase in rat liver peroxisomes. Journal of Biological Chemistry, 255, 9599–9607.
   PubMed Web of Science ®Google Scholar
• MIZOJIRI, K., NORIKURA, R., YOSHIMORI, T., NAKANISHI, M., IWATANI, K., TERUI, Y., KIKUCHI, J. and NAKAGAWA, Y., 1995, Identification of metabolites of a new thromboxane A2 receptor antagonist, S-1452, in rats. Xenobiotic Metabolism and Disposition, 8, 67–81 [in Japanese].
   Google Scholar
• NAGASAKI, T., WATANABE, F., KATSUYAMA, Y., HAMADA, Y., OHTANI, M. and NARISADA, M., 1992, Synthesis of [14C] - and [3H] -labeled(+ )-HR-[la,2a(Z),3b,4a]]-7-[3-[(phenylsulfonyl)amino]-bicyclo-[2.2.1]-hept-2-y1]-5-heptenoic acid, ((+ )- S-145) and its calcium salt (S-1452). Journal of Labelled Compounds and Radiopharmaceuticals, 31, 23–38.
   Google Scholar
• NORIKURA, R., TANAKA, H., YOSIKMORI, T., FUTAGUCHI, S., OKABE, H., NAKANISHI, M., IWAMOTO, Y. and Mizojim, K., 1993b, Studies on the metabolic fate of a new thromboxane A2 receptor antagonist, S-1452 (II): distribution and excretion after single and repeated oral administration to rats. Xenobiotic Metabolism and Disposition, 8, 97–105 [in Japanese].
   Google Scholar
• NORIKURA, R., YOSHIMORI, T., MURAKAMI, T., NAKANISHI, M. and Mizojnu, K., 1993a, Studies on the metabolic fate of a new thromboxane A2 receptor antagonist, S-1452 (I): absorption, distribution, metabolism and excretion after single administration to rats. Xenobiotic Metabolism and Disposition, 8, 83–96 [in Japanese].
   Google Scholar
• NORIKURA, R., YOSHIMORI, T., MURAKAMI, T., NAKANISHI, M. and MizopRi, K., 1993c, Studies on the metabolic fate of a new thromboxane A2 receptor antagonist, S-1452 (IV): absorption, distribution, metabolism and excretion in dogs and monkeys. Xenobiotic Metabolism and Disposition, 8, 113–125 [in Japanese].
   Google Scholar
• OICAMOTO, J., HIRAI, E., KITAGAWA, T. and MATSUBARA, T., 1992a, Capillary gas chromatographic method for the determination of the thromboxane A2 receptor antagonist S-1452 and its metabolites in human plasma. Journal of Chromatography, 583, 43–52.
   Google Scholar
• OICAMOTO, J., HIRAI, E., Suzuki, Y., Fujimoto, K., KITAGAWA, T. and MATSUBARA, T., 1992b, Capillary gas chromatographic method for the determination of the thromboxane A2 receptor antagonist S-1452 and its metabolites in human urine. Journal of Chromatography, 583, 53–62.
   PubMedGoogle Scholar
• OSMUDSEN, H. BREMER, J. and PEDERSEN, J. I., 1991, Metabolic aspects of peroxisomal O-oxidation. Biochimica et Biophysica Acta, 1085, 141–158.
   PubMedGoogle Scholar
• Suzuki, H., Mom, K., YAMADA, J. and SUGA, T., 1990, Contribution of peroxisomal O-oxidation system to the chain-shortening of N-(a-methylbenzyl) azelaamic acid in rat liver. Biochemical Pharmacology, 39, 1975–1981.
   PubMedGoogle Scholar
• VAN VELDHOVEN, P. and MANNAERTS, G. P., 1985, Comparison of the activities of some peroxisomal and extarperoxisomal lipid-metabolizing enzymes in liver and extrahepatic tissues of the rat. Biochemical Journal, 227, 737–741.
   PubMedGoogle Scholar
• VICKERS, S., DUNCAN, C. A., VYAS, K. P., KARI, P. H., ARISON, B., PRAICASH, S. R., RAmgr, H. G., PITZENBERGER, S. M., STOKKER, G. and DUGGAN, D. E., 1990, In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metabolism and Disposition, 18, 476–483.
   PubMed Web of Science ®Google Scholar
• WATANABE, F., MATSUURA, T., SHIRAHASE, K. and OHTANI, M., 1991, Synthesis of metabolites of S-1452, an orally active thromboxane A2 receptor antagonist. Chemical Pharmaceutical Bulletin, 39, 2842–2848.
   PubMedGoogle Scholar
• WEBSTER, L. T. and KILLENBERG, P. G., 1985, Coenzyme A thioesters of benzoic, hydroxybenzoic, phenylacetic, and bile acids. Methods in Enzymology, 77, 430–436.
   Google Scholar
• YAMADA, J., OGAWA, S., HOR1E, S., WATANABE, T. and SUGA, T., 1987, Participation of peroxisomes in the metabolism of xenobiotic acyl compounds: comparison between peroxisomal and mitochondrial O-oxidation of w-phenyl fatty acids in rat liver. Biochimica et Biophysica Acta, 921, 292–301.
   Google Scholar
• YAMAGUCHL Y., BABA, T., Toucui, A. and MATSUBARA, T., 1995, In vitro studies to elucidate the metabolic pathway of (+ )-S-145, a thromboxane A2 receptor antagonist, in rats: evidence for two independent pathways in peroxisomal O-oxidation. Drug Metabolism and Disposition, 23, 1195–1201.
   PubMedGoogle Scholar
• YAMAGUCHL Y., NORIKURA, R., NAKANISHI, M., Toucui, A., YOSHIMORI, T., MURAKAMI, T., BABA, T., Mizojim, K. and MATSUBARA, T., 1996, Sex differences in the metabolism of (+ )-S-145, a novel thromboxane A2 receptor antagonist in rat. Xenobiotica, 26, 613–626.
   PubMedGoogle Scholar
• YASUI, K., ASANUMA, F., FURUE, Y. and ARIMUR A., 1997, Involvement of thromboxane A2 in antigen-induced nasal blockage in guinea pigs. International Archives of Allergy and Immunology, 112, 400–405.
   PubMedGoogle Scholar
• YOSHIDA, Y., YAMADA, J., WATANABE, T., SUGA, T. and TAKAYAMA, H., 1990, Participation of the peroxisomal O-oxidation system in the chain-shortening of PCA16, a metabolite of the cytosine arabinoside prodrug, YNK01, in rat liver. Biochemical Pharmacology, 39, 1505–1512.
   PubMed Web of Science ®Google Scholar